TG THERAPEUTICS, INC. 8-K

What Happened
TG Therapeutics, Inc. (TGTX) announced on January 13, 2026 (via a press release) preliminary fourth-quarter and full-year 2025 net product revenue figures and provided revenue guidance for 2026 along with anticipated development milestones. The disclosure was made under Item 7.01 (Regulation FD Disclosure) and the press release was furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Date of disclosure: January 13, 2026.
• Nature of disclosure: preliminary Q4 and full-year 2025 net product revenue, 2026 revenue guidance, and anticipated development milestones (per the company press release).
• Filing detail: press release attached as Exhibit 99.1; cover page included as Inline XBRL (Exhibit 104).
• Item reported: 7.01 (Regulation FD Disclosure) and exhibits listed under Item 9.01.

Why It Matters
Revenue results and forward revenue guidance are key inputs for investors assessing near-term commercial performance and expectations for TG Therapeutics. Preliminary product revenue and year-ahead guidance can influence market expectations for upcoming quarterly results and the company’s valuation, while disclosed development milestones inform investors about the timing and progress of the company’s clinical and product plans. The Regulation FD filing ensures the information was broadly disclosed to the market and is available in the company’s SEC filing for investor review.